Table 1

Baseline characteristics and demographic data of enrolled patients presented by dose level

Dose level cohortDL1
n=3
DL2
n=4
DL3
n=6
Overall
n=13
Age
 Mean (SD)58.3 (4.93)61.5 (12.66)59.8 (8.93)60.0 (8.88)
 Min, Max55, 6446, 7748, 7546, 77
Sex, n (%)
 Male1 (33.3)3 (75.0)5 (83.3)9 (69.2)
 Female2 (66.7)1 (25.0)1 (16.7)4 (30.8)
Race, n (%)
 White3 (100)1 (25.0)5 (83.3)9 (69.2)
 African American02 (50.0)02 (15.4)
 Asian01 (25.0)01 (7.7)
 Other001 (25.0)1 (7.7)
ECOG PS, n (%)
 002 (50.0)3 (50.0)5 (38.5)
 13 (100)2 (50.0)3 (50.0)8 (61.5)
Primary cancer site, n (%)
 Chordoma04 (100)6 (100)10 (76.9)
 Breast1 (33.3)001 (7.7)
 Colorectal1 (33.3)001 (7.7)
 Prostate1 (33.3)001 (7.7)
Current disease status, n (%)
 Locally advanced01 (25.0)5 (83.3)6 (46.2)
 Metastatic3 (100)3 (75.0)1 (16.7)7 (53.8)
Number of prior systemic cancer therapies
 Median10133
 Min, Max9, 121, 12, 41, 12
  • DL, dose level [one semicolon, not two]; ; ECOG PS, Eastern Cooperative Oncology Group Performance Status.